Yuan F, et al. - In this prospective, multicenter, non-randomized controlled pilot study, researchers investigated the therapeutic impacts of tolvaptan in patients with right heart failure with tricuspid insufficiency (TI). Either tolvaptan combined with torasemide (n = 20) or torasemide monotherapy (n = 20; control group) was administered to patients (N = 40) with TI from the Shanghai Chest Hospital and Shanghai Tongren Hospital between March 2015 and June 2016. In the tolvaptan group vs the control group, a remarkable increase in tricuspid annular plane systolic excursion (TAPSE) was observed after 10 days of medication. A significant increase in daily weight losses was also observed in the tolvaptan group as the time of treatment increased. The tolvaptan group experienced 8 adverse events and one serious adverse event, whereas 15 adverse events were recorded in the control group. Overall, tolvaptan might be a useful and safe drug to improve heart function in patients with right heart failure with TI after left heart valve replacement.